IN8bio Advances CAR-γδ T Cell Engineering and Allogeneic Therapy Strategies
INAB•IN8bio’s CSO co-authored a review detailing CAR-γδ T cells, cytokine-armored γδ T cells and bispecific engagers to boost anti-tumor activity across solid tumors and hematologic cancers. The paper also outlines off-the-shelf allogeneic γδ T cell strategies and combination regimens with checkpoint inhibitors and chemotherapy.
1. Publication Focus and Content
IN8bio’s Chief Scientific Officer contributed to a comprehensive review of γδ T cell engineering, highlighting CAR-γδ constructs, cytokine-armored γδ T cells, T cell engagers and antibody-secreting γδ formats designed to enhance tumor targeting.
2. Therapeutic Advantages of γδ T Cells
The review emphasizes γδ T cells’ MHC-independent recognition of stress signals, potential for off-the-shelf allogeneic use without graft-versus-host disease, and synergy with checkpoint inhibitors, chemotherapy, cytokines and bispecific antibodies to overcome immune escape.
3. Pipeline Implications and Clinical Trials
IN8bio’s pipeline includes the INB-600 γδ T cell engager platform, allogeneic INB-100 for high-risk leukemias and autologous INB-200/400 for glioblastoma, with multiple globally recruiting γδ T cell trials signaling growing clinical momentum.
